We developed a new colorimetric method, DNA enzyme immunoassay (DEIA), for detecting specific hybrids of complementary nucleic acids and applied it to the detection of hepatitis B virus (HBV) DNA amplified from serum samples by means of the polymerase chain reaction (PCR) technique. The method is based on the ability of an anti-DNA monoclonal antibody to discriminate between single-stranded and double-stranded DNA. A solid phase was coated with a specific oligonucleotide probe, internal to the amplified region of HBV DNA, via an avidin-biotin bridge. The denatured PCR product was hybridized with the solid-phase probe, and the amplified DNA probe hybrid was then incubated with a monocional antibody specific for double-but not single-stranded DNA. Colonmetric detection of the DNA-antibody complex was achieved by adding an anti-mouse lg antibody labeled with horseradish peroxidase. The combined use of DEIA and PCR can reveal a few HBV genome copies present in a serum sample. This method has several advantages: (a) the sensitivity is adequate for the detection of amplified DNA; (b) the signal is associated with the hybridization event, independently of modifications of the probe or of the amplification primers; and (c) the test is simple and rapid and, most importantly, requires only the standard facilities of a routine clinical laboratory.
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Polymerase chain reaction (PCR) (1, 2) potentially represents the key for the entry of DNA probe assays into clinical laboratories.4 PCR allows in vitro amplification of very small amounts of nucleic acid in a sample before hybridization. This property of PCR circumvents the problems of sensitivity affecting the use of nucleic acid hybridization assays, which often still require the use of radioactive signals. For these reasons, PCR is an important advance in the field of diagnostic research. The validity and versatility of PCR are demonstrated in Consorzio per le Biotecnologie, Consiglio Nazionale delle Ricerche (CNR), Institute of Chemistry, Medical School, P. le Spedali Civili, 1, 25123 Brescia, Italy.
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Received September 24, 1990 ; accepted December 28, 1990. numerous reports describing its applications to the detection of nucleic acids of infectious agents, to the study of inherited disorders, and to human leukocyte antigen (HLA) typing (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) .
One of the problems that still confine PCR to research laboratories is the difficulty in detecting specific PCR products: the detection methods are largely based on techniques (e.g., gel electrophoresis, dot-blot) that are not well suited for clinical laboratories. Several isotopic and nonisotopic methods for detecting hybrids between oligonucleotide probes and amplified DNA have been described (16) (17) (18) (19) (20) (21) (22) . Most of these methods involve labeling the probe or the PCR primers with radioisotopes or with molecules acting as specific ligands for enzymelabeled antibodies or other macromolecules. However, these systems require the preparation of labeled reagents specific for each target DNA, and follow analytical schemes that often are not fully compatible with those used in routine diagnostic laboratories.
Here we describe an approach in which the native DNA itself provides the signal by means of its specific hybridization with a probe. In our assay, the hybridization event is revealed by an antibody that selectively reacts with double-stranded but not single-stranded DNA. The method is broadly applicable because the antibody recognizes DNA/DNA hybrids independent of their particular sequence and without labeling either the amplified DNA or the amplification primers. This assay combines the sensitivity of PCR with the simplicity of a conventional immunoassay, making it particularly suitable for the development of diagnostic tests. As the first example of a clinical application, we report here its use for detecting DNA from hepatitis B virus (HBV) in serum samples.
Materials and Methods

Materials
Reagents. All the reagents cited were purchased from Sigma Chemical Co., St. Louis, MO, unless otherwise specified.
Primers, probes, and PCR product size. The primers used for amplification in plasmid PADW2 were two oligonucleotides specific for the "core" gene of HBV; they were designed by comparison with available nucleotide sequences (23) 
Clinical Samples
A series of serum samples was collected from subjects with chronic hepatitis. The presence of HBV DNA in these specimens was determined by PCR, followed by Southern hybridization of the amplified DNA. These samples were also tested with a commercial DNA probe kit (Genostics Hepatitis B viral DNA; Abbott Labs., North Chicago, IL) that quantifies HBV DNA in serum. All the patients selected for this study were HBsAg and HBcAg positive, and anti-HBs negative; seven patients (A47, A38, A64, AlOl, A93, A1O8, A71) were HBeAg negative and anti-HBe positive; and the others were HBeAg positive and anti-HBe negative. Serum samples from blood donors that repeatedly gave negative results by PCR were used as negative controls. Amplification ofHBVDNA from serum samples. We extensively boiled100 L of each serum for 45 mm in a i.5-mL Eppendorf tube,centrifuged this for 20 mm at 12 000 x g at 4#{176}C, then added 5 mL of the supernate directly to the PCR mixture. The amplification efficiency obtained with this protocol was equivalent to that obtained with a published method for extracting HBV DNA from serum samples (27) (data not shown). The PCR procedure used with these samples was the same as that used to amplify the recombinant plasmid. Spleen cells from a 10-month-old nonimmunized MRLIIpr mouse were fused with the SP2/O myeloma line (kindly provided by Dr. P. A. Cazenave, Institute Pasteur, Paris). Supernates from wells containing growing hybridomas were tested with native or denatured DNA. In brief, culture supernates were added to plastic wells coated with native or heat-denatured fetal calf DNA (10 mg/L). The plates were incubated overnight at 4#{176}C, washed, and re-incubated for 6 h with 1251-labeled rabbit anti-mouse immunoglobulin. After washing the plates, we measured the bound radioactivity in a gamma counter. Only those hybridomas displaying activity against native DNA but not against denatured DNA were selected for further studies and cloned by conventional methods.
Preparation of mAb 27-14-D9. The immunoglobulun fraction used in the experiments was prepared as follows: 300 mL of supernates from a culture containing 2 x iO cells of cloned27-14-D9 hybridoma were harvested and concentrated 10 times. The protein fraction containing specific antibodies was precipitated with sodium sulfate, 180 g/L. Alter centrifugation, we resuspended the pellet in 15 mL of isotonic saline (sodium chloride, 9 g/L) and extensively dialyzed it against phosphate-buffered saline (PBS), pH 7. For biochemicalcharacterization, we absorbed 4 mL ofthe concentrated supernate on ProteinA-Sepharose (Pharmacia,Uppsala,Sweden) and eluted the specific antibodies with glycine. Cl buffer, 100 mmolfL, pH 4.
Southern blot. One-fifth of the amplification reaction mixture was electrophoresed, transferred to a Hybond N membrane (Amersham, Little Chalfont, Bucks., U.K.), and exposed for5 miii under ultraviolet light(254nm in N,N'-dimethylformamide (145 mmol/L), and we added 17 ML of this solution to 5 nmol of NH2-modified oligonucleotide resuspended in 10 ML of doubly distilled H2O. Then we added 20 ML of sodium borate buffer, 1 mollL, pH 8.5, and brought the mixture to 100 ML with doubly distilled H2O. In these conditions, the molar ratio between N-hydroxysuccinamidobiotin and DNA was 500:1, which we had determined in preliminary experiments was the optimal molar ratio for preparing biotinylated oligonucleotides (data not shown).
After incubating the mixture overnight at room temperature, we separated the biotinylated oligonucleotide from the excess biotin by passing the mixture through a Sephadex G-15 column (Pharmacia), previously calibrated in TNE buffer (per liter, 50 mmol of Tris . Cl, pH 7.5, 150 mmol of NaC1, and 10 mmol of EDTA). TNE was also used as the elution buffer. We measured the absorbance of 1-mL fractions at 260 and 280 nm, pooled the fractions containing the DNA peak, and precipitated them by adding, in this order, 0. (DEJA) . We immobilized the probe, 5 ng/well, onto the solid phase as described above. The solid phase was washed four times, just before use, with 200 ML of washing solution: 6.7 mmol/L of phosphate buffer, pH 6.4, containing 0.13 mol of sodium chloride, 40 mg of Cialit (2-ethylmercurithio-5-ben.zoxalcarboxylic acid, sodium salt), and 1 mL of Tween 20 per liter; this solution was used also in all the other washing steps. The crude PCR mixes were denatured on a heat block for 10 mm at 100 #{176}C and then quickly cooled on ice for 5 miii. We diluted 20 ML of the PCR product fivefold in hybridization solution B (ix SSC, 2 x Denhardt's solution, 10 mmol/L Tris#{149} Cl buffer, pH 7.5, and EDTA, 1 mmoIJL), added this to the coated wells, and incubated for 1 h at 50 #{176}C in an oven. After four washings, we added to each well 100 ML of the standard preparation of the mAb 27-14-D9 diluted 1000-fold in PBS (pH 7.5) containing 100 mL of fetal calf serum (FCS) per liter. After a 1-h incubation at 37 #{176}C and four washings, the bound antibody in each well was detected by adding 100 ML of horseradish peroxidaselabeled rabbit anti-mouseIg antibody (Sorin Biomedica) diluted 20000-fold in the PBS-FCS reagent, incubating for 1 h at room temperature, washing four times, then adding 100 ML of the ETI-IEMA chromogen/substrate mixture (tetramethylbenzidine, 27 g/L, hydrogen peroxide, 0.1 mL/L), and allowing the colorimetric reaction to develop for 30 mm at room temperature in the dark. After stopping the reaction with 200 ML of 1 mollL sulfuric acid, we measured the absorbance of each well at 450 nm with a spectrophotometer.
Results
Preparation of Anti-DNA Antibodies
To produce anti-DNA antibodies, we developed a series of hybridomas, using spleen cells from MRL/lpr mice. We chose this particular strain of mice because it spontaneously develops a genetically transmitted disease characterized by the production of high concentrations of anti-DNA antibodies, most of which belong to the IgG class. Indeed, from one fusion experiment with spleen cells from a nonimmunized mouse, we obtained 33 hybridomas that reacted with fetal calf thymus DNA. However, only four of the hybrids produced antibodies that differentially reacted with double-and singlestranded DNA. Figure IA shows that the mAb 15-18-Fl (IgG) displayed the highest activity against native DNA; however, we did not use it in the assay because it also reacted, to a lesser degree, with the denatured molecule ( Figure 1B) . The 27-14-D9 hybridoma (belonging to IgG class), on the other hand, appeared to best DEIA for Detecting Amplified DNA
The overall scheme of DEIA is based on the following steps: (a) presaturation of avidin-coated solid phases with biotunylated probe, (b) hybridization of solid-phase probe with denatured amplified DNA, (c) incubation with anti-DNA antibody (27-l4-D9), (d) incubation with enzyme-labeled anti-mouse Ig antibody, and (e) chromogenic reaction and blocking. We extensively analyzed each of these steps with respect to the time-course of the reaction, the amount of reagents added (including the amount of PCR product), the antibody titrations, the temperature of the reactions, and the composition of the chromogen/substrate, buffers, and washing solution.
The design of the assay is shown in Figure 2 . In a series of pilot experiments we determined the optimal conditions for obtaining a clear-cut signal of specific DNAJ DNA hybrids between the core CD1 probe and the 447-bp core fragment obtained by PCR with PADW2 as H"
template. The critical variables were the following: the amount of probe immobilized on the wells, the titer of the mAb 27-14-D9, and the incubation time of the anti-DNA antibody. By examining the effects of modulating these variables, we obtained the optimal experimental conditions detailed in Materials and Methods. The specificity of DEIA was determined by loading different amplification products obtained from different target DNAS on CD1-coated wells. The amplified DNAs used for these experiments were as described in Materials: a 447-bp fragment from the core region of HBV DNA, a 268-bp fragment from the HBV S gene, a 115-bp product from the HIV-1 gag gene, a 234-bp product from the DQ alpha gene, and a 241-bp product from the HLA DQ-beta gene. Figure 3 showsthat a positive signal was obtained only with the "core" 447-bp fragment. All of the controls, which contained 2 pg of irrelevant amplified DNA, gave negative results.
To determine the reproducibility and the cutoff value of DEIA, we analyzed several replicates of the amplified core fragment. Three different dilutions of the plasmid PADW2 were amplified with Cl and C2 primers and tested in 25 replicates in the same experiment (withinrun variation). We also performed 25 different experiments to test between-run variability. We analyzed by DEIA different amounts (1 pg to 300 pg) of this standard DNA. As shown in Figure 4 , the limit of detection of this assay is about 1 ng of specific DNA. The cutoff value in this experiment, calculated as described above, was 0.145 A.
To verify the combined sensitivity of PCR and DEIA, we amplified for 35 cycles serial dilutions of PADW2 plasmid; the amount of plasmid added to the PCR mixtures ranged from 1.3x 106 to 1.3x 10 copies. We analyzed 20 ML of each reaction mixture by Southern hybridization. The results of this analysis are shown in Figure 5B . The signal obtained by the amplification of about 10 genomes present in the initial preparation is clearly visible. We also analyzed 20 ML of each reaction mixture by DEIA. As Figure 5A shows, the signal corresponding to the lO-genomes sample was strongly positive (1.5 absorbance units). Note that PCR-DEIA is roughly linear over 3 logs of target concentration, probably because the probe is saturated by small amounts of amplified DNA.
Detection of HBV DNA Amplified from Serum Samples
These results suggested that the performance of the DEIA was adequate to specifically reveal any PCR product as an alternative to Southern blot, dot-blot, or any other detection method commonly used to detect PCR products by hybridization analysis. To verify the general applicability of the method, we used PCR and DEIA to detect HBV DNA in serum samples. Because human serum may contain inhibitors of the PCR, we had to verify whether the protocol of serum treatment described in Materials and Methods was adequate for routinely amplifying HBV DNA from clinical samples. We serially diluted a serum sample obtained from a chronic hepatitis patient with HBV-negative serum from a healthy blood donor; we then amplified and analyzed the sample by Southern hybridization. The HBV DNA content of each undiluted serum had been previously determined by the Abbott Genostics kit. Figure 6B shows that our protocol allows the detection, in Southern blot, of 15 HBV genomes initially present in the sample. Amplified dilutions of an infected serum analyzed by DEIA ( Figure 6A) show that the sensitivity of PCR-DEIA is the same as that obtained with the plasmid model. Collectively, these results establish that the protocol we used for serum treatment efficiently neutralizes or removes PCR inhibitors that accessible to the polymerase. To determine the effect of serum on the efficiency and reproducibility of the assay, we tested by DEIA PCR products obtained from HBV DNA-positive and from HBV DNA-negative sera. We prepared 25 replicates for each sample and tested them in separate experiments. Table 2 shows that both within-run and between-run CVs are equivalent to those obtained with the plasmidderived PCR products. this analysis are reported in Table 3 . A clear-cutposi-1302d Sera 27-A14, 3-A108, 9-A171, and l5-A29 gave negative results with the Abbott Genostics kit but gave a positive signal in Southern blot and were also positive by DEIA. Serum 7-A47, on the other hand, was weakly positive by Southern blot as well as by DEIA. These results demonstrate a 100% correspondence between the results obtained by DEJA and by Southern hybridization. 21 reduce probe sensitivity. Alternatively, amplifying DNA target sequences in vitro through PCR may provide the ideal solution to the problem of sensitivity. Although the extensive utilization of PCR in clinical 
Between-run
MeanA,, SD CV, % laboratories still has some drawbacks, its exquisite sensitivity and its ease of automation make it the natural candidate for the development of new-generation clinical assays based on DNA probes. This evolution, however, needs further advances in the areas of both configuration and readout. We have described a sensitive, nonisotopic assay for the detection of hybridized DNA molecules. The assay has two parts: the amplification of the target sequence by PCR and a hybridization assay that allows specific, rapid, and convenient detection of the amplified product. This assay is based on the simple principle of treating hybridized DNA the same as any conventional antigen. Using this strategy, we were able to develop a hybridization assay configured in an immunoassay-like format. Furthermore, the particular characteristics of the anti-DNA antibody revealed the event of hybridization between any complementary DNA sequences, making this method extremely versatile. The assay is based on a ___________________________________________ mAb that recognizes double-stranded but not single- stranded DNA. An anti-nucleic acid antibody has recently been used to quantify mRNA in biological samples (28) . However, that antibody selectively detects DNAJRNA hybrids only and cannot distinguish singlestranded from double-stranded DNA. The 27-14-D9 mAb, on the other hand, binds hybrids between probe and amplified DNA, but cannot react with the immobilized capture oligonucleotide or with nonspecific amplified sequences, which are removed after the hybridization step. Although we chose a format based on the immobilization of the probe through an avidin-biotin interaction, the method can also be applied to other analytical schemes that do not require any modification of the probe (e.g., covalent link of the probe onto a solid phase, or immobilization of the probe onto nylon membranes, or a sandwich assay format).
Anti-DNA antibodies are spontaneously produced by particular strains of mice that develop genetically transmitted authimmune diseases (29) . Most of these molecules, however, do not distinguish double-from single-stranded DNA or do not have an affinity constant high enough to be used in an inununoassay format.
Indeed, the hybridoma 27-14-D9 was the only one, among the many screened, that produced antibodies of the desired class and with the appropriate characteristics of affinity constant and specificity. The sensitivity, specificity, and reproducibility of our hybridization assay, initially determined with plasmid DNA, could be easily reproduced with biological samples. The study of a series of samples obtained from patients with chronic hepatitis showed that the results obtained with DEJA are completely concordant with the data achieved by Southern hybridization. Both Southern hybridization and DEJA yielded greater numbers of positive results than did the other methods tested. Several samples that were positive by Southern hybridization and by DEJA were not detectable by ethidiurn bromide-stained gels (samples 3-A108, 7-A47, 8-38, 9-A171, and 27A-14). Although gel electrophoresis plus ethidiuxn bromide staining is a simple and rapid method for detecting PCR products, it has two main drawbacks: its sensitivity is inadequate to reveal a few nanograms of DNA, and the occurrence of a band of the expected size is not definitive proof of the specificity of the amplification. An assay based on a hybridization test, conversely, is far more sensitive and, moreover, demonstrates the specificity of the PCR product.
All the negative controls tested by DEJA repeatedly gave results below the cutoff value. We emphasize that these results were obtained after an extremely simple serum treatment involving only the boiling of the biological sample for 45 mm. This procedure gives highly reproducible results and eliminates the time-consuming requirement of chemical DNA extraction. From receiving the biological sample to obtaining results took 7-8 h, including DNA amplification, but additional improvements, such as using 27-14-D9 mAb directly coupled to the enzyme, should cut this time substantially.
We assessed the clinical specificity of the assay by testing a limited series of positive and negative samples.
Further work is needed to gain a complete clinical validation of PCR-DEIA, but these preliminary data made us confident of the accuracy of the assay.
A major problem, however, is the ease of contaminating reagents by carryover in PCR, a dramatic and well-known factor limiting the application of PCR in a routine laboratory. However, many precautions can be taken to control contamination risks. We used only ready-for-use PCR mixtures, which had been aliquoted in the reaction tubes and frozen at -20 #{176}C until use.
When performing PCR, therefore, we added only the sample and the enzyme to each tube. We routinely check these reaction mixtures before use, to exclude contamination. Also important is the use of two or more negative controls in each experiment. In each run, we amplified one negative control with non-HBV DNA (plasmid pBr322 DNA), one negative control with negative serum, and two negative controls not containing any DNA.
The conditions used in this study were determined with a 75-bp immobilized probe and an amplified product of 447 bp. However, we have recently found that the same performance can be achieved with a 20-bp probe and with an amplified DNA fragment of 143 bp (data not shown). In other words, this assay seems suitable to perform in a wide range of combinations of target DNA/probe sizes. This fact is of concern for the further application of DEJA to other diagnostic systems. Here we have described the application of DEJA in detecting amplified HBV genes; however, we have also successfully used this test for HLA typing and to detect genomic mutations responsible for genetically transmitted diseases. Using conditions similar to the ones described here, we have also demonstrated that this hybridization assay can detect one or two base mismatches between the probe and the amplified DNA (G. Mantero et al., manuscript in preparation).
The DEJA test is perfectly compatible with standard enzyme-linked immunosorbent assay equipment for pipetting, washing, and reading results, permitting the processing of large numbers of samples in clinical laboratories. Furthermore, the fact that DEJA uses the same washing solution, even to remove unbound DNA, and involves the same components routinely used for iminunoassays, makes the procedure potentially completely automatable, simply by using the standard equipment of a routine diagnostic laboratory.
In conclusion, we describe a method for specifically detecting amplified DNA that may facilitate the application of DNA probes technology in the clinical laboratory. The successful development of practical techniques for detecting nucleic acid in clinical samples may markedly improve the care of patients and facilitate the understanding of human pathological conditions.
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